Headquartered in Athens, Brain Therapeutics specialises in the in-licensing and commercialisation of pharmaceutical products in the CNS therapy area
Neuraxpharm, a pharmaceutical company focused on the central nervous system (CNS), has announced the expansion of its business in Southeast Europe through the acquisition of Brain Therapeutics, a CNS-focused marketing and distribution company with experience of CNS products in Greece, Cyprus and the Balkan countries.
Headquartered in Athens, Brain specialises in the in-licensing and commercialisation of pharmaceutical products in the CNS therapy area to address the needs of patients with mental, neurological, neurodevelopmental or neurodegenerative disorders, as well as anaesthesia and pain.
Through this acquisition, Neuraxpharm is able to bring its products to the Greek market through Brain’s local market access. Buccolam, a product for the emergency treatment of children and adolescents with epilepsy, will be among the products offered. The company has expanded its activities from two to 19 European countries in the past five years with five of those countries added in the last 12 months.
Dr Jörg-Thomas Dierks, CEO of Neuraxpharm, said: "The acquisition of Brain Therapeutics will significantly strengthen our successful activities in the commercialization of CNS products in Greece, Cyprus and the Balkan countries. We are excited to be able to supply patients in Southeast Europe with our products more efficiently in future. This acquisition brings us one step closer to our goal of addressing the unmet medical needs of CNS patients across Europe."
George Pavlakis, founder of Brain Therapeutics, added: "We are delighted to become part of a leading European CNS player and look forward to working with the dynamic, experienced and high performing team at Neuraxpharm. We are excited about our future with the Neuraxpharm Group and the opportunity to contribute our expertise in the CNS field. Together, we will be able to provide further innovative CNS products to patients in Greece and Southeast Europe."
George Pavlakis will be the General Manager of Neuraxpharm in Greece and any neighbouring countries that join the commercial area.